secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2026-08-10T12:43:36+00:00
Accession:  0001193125-26-341385
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum CFO Musso takes on principal accounting officer role as Tourangeau departs
--------------------------------------------------------------------------------

- Greg Tourangeau, VP Finance and principal accounting officer, departs Fulcrum effective August 7, 2026.
- CFO Alan Musso appointed principal accounting officer effective August 7, 2026, succeeding Tourangeau.
- Musso receives no additional compensation for the added principal accounting officer duties.
- No family relationships or material interests involving Musso were disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312526341385/0001193125-26-341385-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312526341385/fulc-20260807.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-341385

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer